Coronavirus crisis
Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights…
The Australian – Research Special Report 2020
The Australian – Research Special Report 2020
A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…
Pharmafiles 2020: Synthetic Anti-Infectives
Pharmafiles 2020: Synthetic Anti-Infectives
AMR is a ticking time bomb argues Recce CEO James Graham…
H.C. Wainwright Global Life Sciences Conference
H.C. Wainwright Global Life Sciences Conference
Click here for full Press Release and Presentation
AusBiotech Journal 2020 Vol 30
AusBiotech Journal 2020 Vol 30
A NEW CLASS OF ANTIBIOTICS
AusBiotech Journal 2020 Vol 30
AusBiotech Journal 2020 Vol 30
ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs
PharmaShots Interview w Recce CEO James Graham
PharmaShots Interview w Recce CEO James Graham
James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
AusBiotech Journal 2021 Vol 31
AusBiotech Journal 2021 Vol 31
A REVOLUTIONARY APPROACH against antimicrobial resistance
Recce tapping European investor interest
Recce tapping European investor interest
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
Recce tapping European investor interest
Recce tapping European investor interest
Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.